NEKTAR THERAPEUTICS
NKTR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NKTR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NKTR
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunomodulatory therapies for autoimmune diseases and oncology, with its lead candidate rezpegaldesleukin entering Phase 3 trials for atopic dermatitis.
Key risk: Dependence on rezpegaldesleukin
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.48B
Cash Runway
26.5 moLead Asset
NKTR-255 (Phase 1)Next Catalyst
Phase3_Topline · Dec 1, 2028Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 7 clinical trials · 2 catalysts for NEKTAR THERAPEUTICS.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunomodulatory therapies for autoimmune diseases and oncology, with its lead candidate rezpegaldesleukin entering Phase 3 trials for atopic dermatitis.
- Lead candidate rezpegaldesleukin (NKTR-358) achieved statistically significant Phase 2b results supporting advancement into Phase 3 development for atopic dermatitis [sec · filed 2026-04-24].
- Cash and equivalents of $39.3M as of 2026-06-30 [sec]; total revenue of $10.1M and net loss of -$40.6M for the same period [sec].
- Phase 3 studies of rezpegaldesleukin in atopic dermatitis are planned to initiate in mid-2026 [sec · filed 2026-04-24].
- The company is also developing NKTR-0165 (TNFR2 agonist) and NKTR-0166, with IND-enabling studies ongoing [sec · filed 2025-04-25].
- Nektar sold its manufacturing facility in Huntsville, Alabama in December 2024, which does not affect royalties or milestones under existing agreements [sec_mda · as of 2026-05-08].
What works
- Rezpegaldesleukin has shown statistically significant Phase 2b results, supporting advancement to Phase 3 [sec · filed 2026-04-24].
- The company held a successful Type C Pharmacology meeting with the FDA for rezpegaldesleukin [sec · filed 2026-04-24].
- Nektar has a pipeline of early-stage candidates (NKTR-0165, NKTR-0166) targeting autoimmune diseases and oncology [sec · filed 2025-04-25].
What to weigh
- Nektar is highly dependent on the success of rezpegaldesleukin; failure would significantly harm the business [sec_mda · as of 2026-08-14].
- Clinical drug development is lengthy and uncertain with a high risk of failure at every stage [sec_mda · as of 2026-08-14].
- The company has a net loss of -$40.6M as of 2026-06-30 and expects R&D expense to increase significantly in 2026 [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Rezpegaldesleukin Phase 2b results support Phase 3 initiation
“We achieved statistically significant results from our Phase 2b studies that support advancing rezpegaldesleukin into Phase 3 development with planned initiation of Phase 3 studies of rezpegaldesleukin in atopic dermatitis in mid-2026.”
SEC filings · April 24, 2026
High dependence on rezpegaldesleukin
“we are highly dependent on the success of rezpegaldesleukin (previously referred to as NKTR-358) and our business will be significantly harmed if rezpegaldesleukin does not continue to adva”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2028-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica — Topline results from a Phase 3 study of rezpegaldesleukin in atopic dermatitis are expected.
- 2029-01-01 · Phase3_Topline · moderate-to- — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica — Topline results from another Phase 3 study of rezpegaldesleukin in moderate-to-severe atopic dermatitis are expected.
Risks & what to watch (3)›
Key risks
- Dependence on rezpegaldesleukin — Business significantly harmed if rezpegaldesleukin fails to advance [sec_mda · as of 2026-08-14].
- Clinical trial uncertainty — Drug development is inherently uncertain with high risk of failure at every stage [sec_mda · as of 2026-08-14].
- Financial losses and cash burn — Net loss of -$40.6M as of 2026-06-30; R&D expense expected to increase significantly in 2026 [sec_mda · as of 2026-05-08].
What to watch
- Initiation of Phase 3 studies for rezpegaldesleukin in atopic dermatitis, planned for mid-2026 [sec · filed 2026-04-24].
- Top-line Phase 2b data for rezpegaldesleukin in alopecia areata, expected in Q4 2025 [sec · filed 2025-06-24].
- Full 52-week data from the RESOLVE-AD trial expected in early 2026 [sec · filed 2025-06-24].
- IND submission for NKTR-0165, targeted for second half of 2025 [sec · filed 2025-04-25].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run NEKTAR THERAPEUTICS through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NEKTAR THERAPEUTICS facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
26.5 months
D/E 0.21 · 0% dilution
Lead: Phase 2
2 candidates
2 upcoming, next in ~824d
0 buys · 8 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
208
Total value held
$2.05B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,303,188 | $309.6M |
| bvf inc/il | 2,559,595 | $184.2M |
| vanguard capital management llc | 2,394,110 | $172.3M |
| two seas capital lp | 1,959,178 | $141.0M |
| two sigma investments, lp | 930,741 | $67.0M |
| susquehanna international group, llp | 903,190 | $65.0M |
| woodline partners lp | 830,670 | $59.8M |
| prosight management, lp | 735,000 | $52.9M |
| blackrock, inc. | 692,650 | $49.8M |
| citadel advisors llc | 665,431 | $47.9M |
Showing top 10 of 208 institutional holders of NEKTAR THERAPEUTICS. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 12.9%
- Days to cover
- 4.3
- Shares short
- 3,663,438
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NKTR short interestGovernance
Frequently asked questions
What is the AI investment thesis for NEKTAR THERAPEUTICS?
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunomodulatory therapies for autoimmune diseases and oncology, with its lead candidate rezpegaldesleukin entering Phase 3 trials for atopic dermatitis.
What is NEKTAR THERAPEUTICS's lead drug candidate?
NEKTAR THERAPEUTICS's most advanced tracked candidate is NKTR-255 (Phase 1) for Head and Neck Squamous Cell Carcinoma.
What is NEKTAR THERAPEUTICS's next catalyst?
NEKTAR THERAPEUTICS's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Effica" — expected December 1, 2028.
Who is the CEO of NEKTAR THERAPEUTICS?
Mr. Howard W. Robin is the chief executive officer of NEKTAR THERAPEUTICS (NKTR).
Where is NEKTAR THERAPEUTICS headquartered?
NEKTAR THERAPEUTICS (NKTR) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.